Phibro Animal Health Corporation’s PAHC focus on advancing vaccine technologies is poised to drive growth in the upcoming quarters. The company’s global growth prospects look encouraging.

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning. Other analysts ...

Phibro Animal Health PAHC has seen impressive momentum in the past year, with its shares soaring 82.8%. It has significantly outperformed the 9.6% rise of the industry and the S&P 500 Composite ...

Short PAHC slightly under 22.22, target n/a, stop loss @ 22.28 Check the time stamp on this data. Updated AI-Generated ...

StockNews.com downgraded shares of Phibro Animal Health (NASDAQ:PAHC – Free Report) from a strong-buy rating to a buy rating in a research report released on Friday. Other research analysts have also ...

Phibro Animal Health Corporation’s PAHC focus on advancing vaccine technologies is poised to drive growth in the upcoming quarters. The company’s global growth prospects look encouraging. Yet, adverse ...